SCHEMBL1643754

SCHEMBL1643754

CCOC(=O)Cc1ccc(OC)c(Oc2ccc(NC(=O)C3CCCCC3)cc2CN2CCOC2=O)c1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SSTR1 P30872 1/20 0.42
SSTR5 P35346 1/20 0.42
HRH1 P35367 1/20 0.42
L3MBTL1 Q9Y468 2/20 0.41
LMNA P02545 3/20 0.41
ALDH1A1 P00352 2/20 0.41
KMT2A Q03164 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
HTT P42858 1/20 0.41
POLB P06746 2/20 0.40
GAA P10253 1/20 0.39
TP53 P04637 3/20 0.39
MEN1 O00255 1/20 0.39
ATM Q13315 1/20 0.39
KDM4E B2RXH2 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
CNR1 P21554 1/20 0.37
CNR2 P34972 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1643239 0.91 CYP3A4 (0.46) SSTR1SSTR5HRH1LMNAALDH1A1
SCHEMBL1643912 0.87 L3MBTL1 (0.44) L3MBTL1LMNAALDH1A1KMT2ASMN1; SMN2
SCHEMBL1643702 0.86 L3MBTL1 (0.51) L3MBTL1LMNAALDH1A1KMT2ASMN1; SMN2
SCHEMBL1644798 0.86 CYP3A4 (0.51) L3MBTL1LMNAALDH1A1KMT2ASMN1; SMN2
SCHEMBL1643253 0.85 L3MBTL1 (0.46) L3MBTL1LMNAALDH1A1KMT2ASMN1; SMN2
SCHEMBL1644071 0.84 L3MBTL1 (0.41) L3MBTL1LMNAALDH1A1KMT2ASMN1; SMN2
SCHEMBL1643664 0.84 CPT1A (0.44) L3MBTL1LMNAALDH1A1KMT2ASMN1; SMN2
SCHEMBL13761020 0.84 L3MBTL1 (0.41) L3MBTL1LMNAKMT2ASMN1; SMN2HTT
SCHEMBL1644812 0.83 MAPT (0.44) L3MBTL1LMNAALDH1A1KMT2ASMN1; SMN2
SCHEMBL1643160 0.83 L3MBTL1 (0.47) L3MBTL1ALDH1A1KMT2APOLBGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8242145-B2 Cyclic diaryl ether compounds as antagonists of prostaglandin D2 receptors PANMIRA PHARMACEUTICALS, LLC (US) 2012-08-14 US disclosed
US-8242145-B2 Cyclic diaryl ether compounds as antagonists of prostaglandin D2 receptors PANMIRA PHARMACEUTICALS, LLC (US) 2012-08-14 US disclosed
US-8242145-B2 Cyclic diaryl ether compounds as antagonists of prostaglandin D2 receptors PANMIRA PHARMACEUTICALS, LLC (US) 2012-08-14 US disclosed
US-20110098302-A1 CYCLIC DIARYL ETHER COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS AMIRA PHARMACEUTICALS, INC. (US) 2011-04-28 US disclosed
US-20110098302-A1 CYCLIC DIARYL ETHER COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS AMIRA PHARMACEUTICALS, INC. (US) 2011-04-28 US disclosed
US-20110098302-A1 CYCLIC DIARYL ETHER COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS AMIRA PHARMACEUTICALS, INC. (US) 2011-04-28 US disclosed
WO-2009102893-A2 CYCLIC DIARYL ETHER COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 receptors AMIRA PHARMACEUTICALS, INC. (US) 2009-08-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098302-A1 CYCLIC DIARYL ETHER COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS PTGDR, PTGDR2, PTGER1 SSTR1 1128/4885SSTR5 1278/4885HRH1 216/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.